


Thursday 9 February 2012



## Australian Securities Exchange Announcement

### **EXPANDED U.S. COVERAGE FOR L-DEX TESTING & FIRST PATIENT ENROLLMENT IN THE STANFORD REGISTRY**

Brisbane, Australia – ImpediMed Limited (ASX: IPD) (“ImpediMed” or “the Company”) reports today expanded U.S. coverage for the use of its L-Dex® medical device as an aid in the clinical assessment of unilateral lymphoedema of the arm in females.

As a result of the passing of the Patient Protection and Affordable Care Act in the U.S., which makes certain indigenous tribes and organizations eligible to access the health plans for federal employees, the Company expects an increase in covered lives for federal healthcare plans from 1 May 2012.

The Company estimates the number of employees of indigenous tribes or organisations who are eligible to access federal health plans is approximately 350,000. Direct family members of these employees are also eligible and include spouse and children up to the age of 26.

As a result, coverage under federal plans could be expected to increase by an estimated 700,000 (estimated range of 500,000 to 900,000) covered lives.

In addition, the Company announces the first patient enrolment into the Stanford Breast Cancer Lymphedema Registry (“the Registry”). As previously announced, Stanford University Medical Center has initiated the Registry which will collect and analyse data from breast centres and physicians offices across the United States. The data collected into the Registry will be mined by the investigators in order to gain insight into the natural history and optimal management of lymphoedema. Patient enrolment will begin to build in the months ahead as the Registry is rolled out to physician sites. Data generated from the Company’s L-Dex® U400 device will make-up one arm of the Registry.

**Greg Brown**  
**CEO**

**ENDS**

**For further information contact:**

**Greg Brown**  
**ImpediMed CEO**  
**T: 61-7-3860-3700**  
**Mobile/Cell: +61408281127**

L-Dex® is a trademark of ImpediMed Limited.

The L-Dex scale is a tool to aid in the clinical assessment of unilateral lymphoedema of the arm in women by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity.

**About ImpediMed**

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: [www.impedimed.com.au](http://www.impedimed.com.au)